{"DataElement":{"publicId":"7153889","version":"1","preferredName":"IWG-MRT Myelofibrosis Cytogenetic Response Status Type","preferredDefinition":"A description of the IWG-MRT myelofibrosis cytogenetic response.","longName":"7153886v1.0:7153852v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"7153886","version":"1","preferredName":"IWG-MRT Myelofibrosis Cytogenetic Response Status","preferredDefinition":"At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. Complete response: eradication of a preexisting abnormality. Partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)_A condition or state at a particular time.","longName":"7158678v1.0:2320064v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"7158678","version":"1","preferredName":"IWG-MRT Myelofibrosis Cytogenetic Remission","preferredDefinition":"At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. Complete response: eradication of a preexisting abnormality. Partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","longName":"C168650","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Cytogenetic Remission","conceptCode":"C168650","definition":"At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. Complete response: eradication of a preexisting abnormality. Partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DB30E7B-1691-7DE9-E053-F662850A7ABB","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2320064","version":"1","preferredName":"Status","preferredDefinition":"A condition or state at a particular time.","longName":"C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC71B93E-037B-5AD9-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D343C17-2DA8-6A02-E053-F662850A5367","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"MALUMK","dateModified":"2020-05-11","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7153852","version":"1","preferredName":"IWG-MRT Myelofibrosis Cytogenetic Response Type","preferredDefinition":"At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. Complete response: eradication of a preexisting abnormality. Partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)_Something distinguishable as an identifiable class based on common qualities.","longName":"7153852v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None of the above","valueDescription":"None of the above","ValueMeaning":{"publicId":"7153853","version":"1","preferredName":"None of the above","longName":"7153853","preferredDefinition":"Does not meet the CR or PR criteria.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D26BCD7-0528-5524-E053-F662850ACB41","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D26BCD7-0541-5524-E053-F662850ACB41","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Not applicable","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5043360","version":"1","preferredName":"Not Applicable","longName":"5043360","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2421E11B-65A6-151D-E050-BB89AD4378BB","latestVersionIndicator":"Yes","beginDate":"2015-11-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-11-09","modifiedBy":"DWARZEL","dateModified":"2018-10-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D26BCD7-054B-5524-E053-F662850ACB41","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D26BCD7-0555-5524-E053-F662850ACB41","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Re-emergence of pre-existing cytogenetic abnormality","valueDescription":"Appearance Pre-existing Cytogenetic Abnormality","ValueMeaning":{"publicId":"7153854","version":"1","preferredName":"Appearance Pre-existing Cytogenetic Abnormality","longName":"7153854","preferredDefinition":"The outward or visible aspect of a person or thing.: Having been present before a specific date or event.: An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Appearance","conceptCode":"C25377","definition":"The outward or visible aspect of a person or thing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pre-existing","conceptCode":"C73621","definition":"Having been present before a specific date or event.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Cytogenetic Abnormality","conceptCode":"C2950","definition":"An irregularity in the number or structure of chromosomes, usually in the form of a gain (duplication), loss (deletion), exchange (translocation), or alteration in sequence (inversion) of genetic material.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D26BCD7-0563-5524-E053-F662850ACB41","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D26BCD7-057C-5524-E053-F662850ACB41","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Partial response (PR)","valueDescription":"Partial response","ValueMeaning":{"publicId":"7153855","version":"1","preferredName":"Partial response","longName":"7153855","preferredDefinition":"Greater than or equal to 50% reduction in abnormal metaphases.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D26BCD7-0586-5524-E053-F662850ACB41","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D26BCD7-059F-5524-E053-F662850ACB41","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Complete response (CR)","valueDescription":"Complete response","ValueMeaning":{"publicId":"7153856","version":"1","preferredName":"Complete response","longName":"7153856","preferredDefinition":"Eradication of pre-existing abnormality.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D26BCD7-05A9-5524-E053-F662850ACB41","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"KUMMEROA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D26BCD7-05C2-5524-E053-F662850ACB41","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7158679","version":"1","preferredName":"IWG-MRT Myelofibrosis Cytogenetic Remission Type","preferredDefinition":"At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. Complete response: eradication of a preexisting abnormality. Partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8):Something distinguishable as an identifiable class based on common qualities.","longName":"C168650:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Cytogenetic Remission","conceptCode":"C168650","definition":"At least 10 metaphases must be analyzed for cytogenetic response evaluation and requires confirmation by repeat testing within 6 months window. Complete response: eradication of a preexisting abnormality. Partial response: greater than or equal to 50 percent reduction in abnormal metaphases. (partial response applies only to patients with at least ten abnormal metaphases at baseline) (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DB2D309-D595-07E5-E053-F662850A1AB8","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D26BCD7-0512-5524-E053-F662850ACB41","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"MALUMK","dateModified":"2020-05-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"TDIS_MPN_mpn_cyto_respon_type","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the cytogenetic response","type":"Alternate Question Text","description":"Specify the cytogenetic response","url":null,"context":"NHLBI"},{"name":"What was the IWG-MRT myelofib","type":"Preferred Question Text","description":"What was the IWG-MRT myelofibrosis cytogenetic response?","url":null,"context":"NHLBI"},{"name":"Specify the current cytogenetic response","type":"Alternate Question Text","description":"Specify the current cytogenetic response","url":null,"context":"NHLBI"},{"name":"Specify the cytogenetic response","type":"Application Standard Question Text","description":"Specify the cytogenetic response","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D3456DB-EE52-0761-E053-F662850AA2E2","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"MALUMK","dateModified":"2020-05-28","changeDescription":".System generated def displayed as alt def. 05/11/2020 KMM; System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}